(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
@ $4.67
发出时间: 15 Feb 2024 @ 02:53
回报率: 4.28%
上一信号: Feb 14 - 04:50
上一信号:
回报率: 11.73 %
Live Chart Being Loaded With Signals
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors...
Stats | |
---|---|
今日成交量 | 1.24M |
平均成交量 | 656 755 |
市值 | 273.95M |
EPS | $0 ( 2024-05-14 ) |
下一个收益日期 | ( $-0.430 ) 2024-06-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.93 |
ATR14 | $0.00800 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Campbell Shannon | Buy | 61 100 | Stock Option (Right to Buy) |
2024-04-10 | Raman Prakash | Buy | 61 100 | Stock Option (Right to Buy) |
2024-04-10 | Campbell Shannon | Buy | 0 | |
2024-04-10 | Raman Prakash | Buy | 0 | |
2024-03-15 | Behbahani Ali | Buy | 3 166 | Common Stock |
INSIDER POWER |
---|
99.07 |
Last 97 transactions |
Buy: 11 965 700 | Sell: 275 000 |
音量 相关性
Black Diamond 相关性 - 货币/商品
Black Diamond 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-437 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2023 |
营收: | $0 |
毛利润: | $-437 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2022 |
营收: | $0 |
毛利润: | $-3.24M (0.00 %) |
EPS: | $-2.33 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.00347 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Black Diamond
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。